Drug intelligence / Profile preview

flucloxacillin

Development stage
Phase 4
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Flucloxacillin is a narrow-spectrum beta-lactam antibiotic of the penicillin class, primarily used to treat infections caused by susceptible Gram-positive bacteria, especially those producing beta-lactamase (penicillinase). It is commonly prescribed for skin and soft tissue infections, bone and joint infections (such as osteomyelitis), ear infections in children, respiratory tract infections, endocarditis, and for surgical prophylaxis against Staphylococcus aureus. Flucloxacillin works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), thereby preventing cross-linking of peptidoglycan chains essential for cell wall strength and integrity. This action leads to bacterial cell lysis and death. It is resistant to degradation by most staphylococcal beta-lactamases due to its isoxazolyl side chain. Flucloxacillin can be administered orally or parenterally (intravenous or intramuscular injection)[1][2][4].

Brand names
FlucFlucilFlucillinFluxinFlxzenFucil
Other names
floxacillinflucloxacilinaflucloxacillineflucloxacillinum
02

Targets

PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on flucloxacillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on flucloxacillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call